Status of DMT as of Jan. 2020

[frodo]

I have tried to merge different sources from UK and the USA removing inconsistencies. Mainly wikipedia and https://www.mstrust.org.uk/about-ms/ms- ... evelopment

Though is not officially considered a distinct course, clinical trials and approval processes consider separately the "highly active RRMS" course. I have made the distinction under the name HA-RRMS.(link)

a) Approved (Main source: wikipedia)

- RRMS: Two interferons (beta-1a and beta-1b), Three immuno-modulators (Glatiramer acetate, Teriflunomide, Dimethyl fumarate), Two S1P modulators (Fingolimod, Siponimod) and Three monoclonal antibodies (Alemtuzumab, Natalizumab, Ocrelizumab).

- HA-RRMS: Alemtuzumab (Lemtrada, see source) and Mitoxantrone.

- SPMS: Siponimod and Cladribine (and Mitoxantrone with restrictions)

- PPMS: Ocrelizumab (and Mitoxantrone with restrictions)

b) On revision (soon to be approved).

- RRMS: The next expected medication could be ([https://www.ptcommunity.com/system/file ... 312750.pdf])

Ozanimod: 2019 - Expected in March 2020
Ofatumumab (Arzerra): Expected 2020
Ponesimod: 2020
Masitinib: 2020
MD1003: 2020
Ublituximab: 2022

c) Phase III

- RRMS: Diroximel fumarate (ALKS 8700), Evobrutinib, Ofatumumab , Ponesimod, Ublituximab

- SPMS: Masitinib, MD1003 (Biotin), Opicinumab (Anti-LINGO-1, BIIB033), Riluzole, Simvastatin

- PPMS: Masitinib , MD1003 (Biotin)

[Petr75]

https://ereska.net/

[NHE]

https://ereska.net/

A translated version...

https://translate.google.com/translate? ... ska.net%2F

[frodo]

https://www.drugs.com/medical-answers/n ... s-3510640/